Acute respiratory distress syndrome (ARDS) is a frequent and serious complication following cardiovascular surgery, while sivelestat has been explored as a potential therapeutic option due to its neutrophil elastase inhibitory effects. However, direct clinical evidence supporting its efficacy remains limited. To address this gap, a study evaluated clinical outcomes among 424 patients receiving sivelestat therapy. The study found that sivelestat significantly reduced the incidence of ARDS and 90-day mortality compared with standard care, with lower rates of ARDS (16.8% [32/190] vs 31.2% [60/192]) and mortality (1.1% [2/190] vs 5.2% [10/192]).
It was also associated with significant reductions in postoperative inflammatory biomarkers, including neutrophil elastase and interleukin-6. There were no significant differences in safety outcomes between the groups. These findings suggest that…
